Propafenone efficacy in treatment of atrial fibrillation paroxysms: a placebo-controlled study
In a placebo-controlled study, propafenone efficacy and safety for pharmaceutical cardioversion in atrial fibrillation (AF) paroxysms were studied. The study included 50 patients aged 28-69 years (mean age 53,9+9,7), with AF paroxysms lasting for less than 48 hours. Participants were randomized to p...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Russo |
| Vydáno: |
«FIRMA «SILICEA» LLC
2005-12-01
|
| Edice: | Российский кардиологический журнал |
| Témata: | |
| On-line přístup: | https://russjcardiol.elpub.ru/jour/article/view/2343 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|